JOURNAL of
ONCOLOGICAL
SCIENCES

CASE REPORT

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALKrearrangement who treated with erlotinib and crizotinib
Doi: 10.1016/j.jons.2018.04.001 - Article's Language: EN
Journal of Oncological Sciences 4 (2018) 111-113
ABSTRACT
Concomitant mutations of echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) can be found rarely in lung adenocarcinoma. We present a case of harboring EML4/ALK rearrangement lung adenocarcinoma who previously received erlotinib. A 42-year-old male who was diagnosed as lung adenocarcinoma and received many series of cytotoxic regimens. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy. After progressive disease, biopsy of new liver lesion showed EML4/ALK rearrangement. Thus crizotinib was administrated. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy and chemotherapy. We conclude that it is important to evaluate for EML4/ALK rearrangement even the patient has EGFR mutation. Concomitant EGFR exon 18 and EML4- ALK mutations can occur in lung adenocarcinoma. EML4/ALK related TKIs may be more effective in these patients.